Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novartis AG's Ending Cash Position for the quarter that ended in Jun. 2026 was €6,611 Mil.
Novartis AG's quarterly Ending Cash Position
declined
from Dec. 2025 (€9,765 Mil) to Mar. 2026 (€5,949 Mil) but then
increased
from Mar. 2026 (€5,949 Mil) to Jun. 2026 (€6,611 Mil).
Novartis AG's annual Ending Cash Position
declined
from Dec. 2023 (€12,281 Mil) to Dec. 2024 (€10,943 Mil) and
declined
from Dec. 2024 (€10,943 Mil) to Dec. 2025 (€9,765 Mil).
Novartis AG Ending Cash Position Related Terms
Novartis AG Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Novartis AG's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Novartis AG's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of €6,611 Mil mean?
Novartis AG (FRA:NOT) has a Ending Cash Position of €6,611 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Novartis AG and its competitors.
Is Novartis AG's Ending Cash Position too high?
Novartis AG's current Ending Cash Position is €6,611 Mil. Overall, Novartis AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Ending Cash Position compare to LLY and JNJ?
Novartis AG's Ending Cash Position of €6,611 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Novartis AG and its competitors. Novartis AG's current Ending Cash Position is €6,611 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT) is currently considered Modestly Overvalued. The stock's GF Value™ is €113.35, compared to a current price of €137.02 — trading 20.9% above its estimated fair value. The current Ending Cash Position is €6,611 Mil. Novartis AG's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Novartis AG (FRA:NOT), the current Ending Cash Position is €6,611 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis AG (FRA:NOT) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued.
The current stock price of €137.02 is trading 20.9% above its estimated GF Value™ of €113.35.
GuruFocus considers Novartis AG to be Modestly Overvalued.
Key valuation signals for FRA:NOT:
Ending Cash Position: €6,611 Mil
GF Value™: €113.35 vs. price of €137.02 (20.9% above fair value)
No single metric tells the full story. See the FRA:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score
Get the complete analysis for FRA:NOT
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NOT has been successfully added to your 
